Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 The second wave in kinase cancer drugs.

Literature DB >> 16465146

The second wave in kinase cancer drugs.

Ken Garber.

Abstract

Entities: Disease

Mesh：

Substances：

Year: 2006 PMID： 16465146 DOI： 10.1038/nbt0206-127

Source DB: PubMed Journal: Nat Biotechnol ISSN： 1087-0156 Impact factor: 54.908

Keyword Cloud
Cited

× No keyword cloud information.

16 in total

Review 1. Principles of safety pharmacology.

Authors: M K Pugsley; S Authier; M J Curtis
Journal: Br J Pharmacol Date: 2008-07-07 Impact factor: 8.739

Review 2. Chemoresistance and targeting of growth factors/cytokines signalling pathways: towards the development of effective therapeutic strategy for endometrial cancer.

Authors: Fengjun Guo; Haina Zhang; Zanhui Jia; Manhua Cui; Jingyan Tian
Journal: Am J Cancer Res Date: 2018-07-01 Impact factor: 6.166

3. Dimethyl Fumarate Inhibits the Nuclear Factor κB Pathway in Breast Cancer Cells by Covalent Modification of p65 Protein.

Authors: Irida Kastrati; Marton I Siklos; Esther L Calderon-Gierszal; Lamiaa El-Shennawy; Gergana Georgieva; Emily N Thayer; Gregory R J Thatcher; Jonna Frasor
Journal: J Biol Chem Date: 2015-12-18 Impact factor: 5.157

Review 4. Inhibitory kappa B Kinases as targets for pharmacological regulation.

Authors: Carly Gamble; Kathryn McIntosh; Rebecca Scott; Ka Ho Ho; Robin Plevin; Andrew Paul
Journal: Br J Pharmacol Date: 2012-02 Impact factor: 8.739

5. The NF-κB Pathway Promotes Tamoxifen Tolerance and Disease Recurrence in Estrogen Receptor-Positive Breast Cancers.

Authors: Irida Kastrati; Stacey E P Joosten; Svetlana E Semina; Luis H Alejo; Svitlana D Brovkovych; Joshua D Stender; Hugo M Horlings; Marleen Kok; Elaine T Alarid; Geoffrey L Greene; Sabine C Linn; Wilbert Zwart; Jonna Frasor
Journal: Mol Cancer Res Date: 2020-04-03 Impact factor: 5.852

10. Identification of novel kinase inhibitors by targeting a kinase-related apoptotic protein-protein interaction network in HeLa cells.

Authors: Z Shi; N An; B M Lu; N Zhou; S L Yang; B Zhang; C Y Li; Z J Wang; F Wang; C F Wu; J K Bao
Journal: Cell Prolif Date: 2014-03-19 Impact factor: 6.831

The second wave in kinase cancer drugs.

Review 1. Principles of safety pharmacology.

Review 2. Chemoresistance and targeting of growth factors/cytokines signalling pathways: towards the development of effective therapeutic strategy for endometrial cancer.

3. Dimethyl Fumarate Inhibits the Nuclear Factor κB Pathway in Breast Cancer Cells by Covalent Modification of p65 Protein.

Review 4. Inhibitory kappa B Kinases as targets for pharmacological regulation.

5. The NF-κB Pathway Promotes Tamoxifen Tolerance and Disease Recurrence in Estrogen Receptor-Positive Breast Cancers.

6. Cell kinase activity assay based on surface enhanced Raman spectroscopy.

Review 7. Kinase mutations in human disease: interpreting genotype-phenotype relationships.

8. The therapeutic potential of LRRK2 and alpha-synuclein in Parkinson's disease.

9. Gain and loss of phosphorylation sites in human cancer.

10. Identification of novel kinase inhibitors by targeting a kinase-related apoptotic protein-protein interaction network in HeLa cells.